Astellas has settled a False Claims case with the Department of Justice over the 2010-2013 marketing of an antifungal medication. Astellas denies the allegations.
DOJ may cost Aegerion patients
March 6, 2014
6:51 pm
The drugmaker’s annual report indicates the company is concerned that an investigation into its marketing could dissuade doctors from prescribing Juxtapid.
Business briefs: Gilead, Shire, The Medicines Co., HHS
February 4, 2013
7:21 pm
HHS wants input for its TXT4Tots childhood advice program, Gilead releases some Hep. C clinical trial data, and Shire settles with the DOJ over disputed marketing practices.
GSK in biggest-ever $3b marketing fraud settlement
GlaxoSmithKline will pay $3 billion to settle state and federal charges that it promoted antidepressants Paxil and Wellbutrin for unindicated uses and withheld safety data on diabetes drug Avandia.
DOJ hit pharmas for $2.2 billion in 2011 False Claims Act cases
Pharmas shelled out $2.2 billion in False Claims Act fines and settlements with the Justice Department this year as the feds’ healthcare fraud haul hit an all-time high.
Former sales rep to argue First Amendment protection in court
A federal appeals court has agreed to hear oral arguments about whether the First Amendment protects a sales rep’s ability to share information about off-label uses of a drug.
CIAs pressure pharma to rethink sales rep compensation
Novartis’s recent off-label settlement with the Department of Justice — to the tune of $422 million — also included the signing of a Corporate Integrity Agreement (CIA) requiring the Swiss-based manufacturer to review incentive-based compensation for reps, and to examine “the extent to which compensation is based on product performance,” according to the CIA.
Forest Laboratories is the latest pharmaceutical company to settle unlawful marketing allegations with a multi-million dollar payout – over $313 million – to the Department of Justice (DOJ), just two weeks after Allergan agreed to pony up $600 million to settle illegal Botox marketing practices.
Allergan drops FDA lawsuit as part of off-label settlement
Before Allergan could begin settlement negotiations with the Department of Justice (DOJ) — which ended with an agreement to pay $600 million on Wednesday — DOJ required the Botox manufacturer to first withdraw a First Amendment lawsuit against the FDA filed last October.
Loading...
MM+M Transform: The Patient, Provider and Payer Engagement Matrix